GSK plc to acquire Nuvalent, Inc
GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full c…
- Buyer
- GSK plc
- Target
- Nuvalent, Inc
- Deal value
- USD 10,600,000,000
- Deal type
- strategic acquisition
